Abbott Laboratories

Abbott Laboratories posted a largely solid third quarter, with adjusted diluted EPS of $1.30 edging past the consensus estimate of $1.30 by 0.05% and growing 7.4% year-over-year, even as revenue of $11.37 billion came in fractionally below the $11.39 billion expected, representing a 0.21% miss despite advancing 6.9% from the prior-year period. The clear engine behind the quarter was Medical Devices, where sales surged 14.8% on a reported basis to $5.45 billion, fueled by continuous glucose monitor sales reaching $2.00 billion, up 20.5%, a trend that is gaining further momentum as Abbott expands retail access for its CGM lineup. Diagnostics remained a headwind, with COVID-19 testing revenue collapsing to $69.00 million from $265.00 million a year ago, masking otherwise steady underlying performance. Adjusted operating margin improved 40 basis points to 23.0% of sales, reflecting ongoing operational discipline. Looking ahead, Abbott reaffirmed its full-year 2025 organic sales growth guidance of 7.5% to 8.0% excluding COVID-19 testing and narrowed its adjusted diluted EPS range to $5.12 to $5.18, reflecting double-digit growth at the midpoint.